3-甲基-5-苯基-4-异噁唑甲醛 | 89479-66-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-甲基-5-苯基-4-异噁唑甲醛
• 中文别名: 3-甲基-5-苯基-4-异唑甲醛
• 英文名称: 3-Methyl-5-phenyl-isoxazole-4-carbaldehyde
• 英文别名: 3-methyl-5-phenylisoxazole-4-carbaldehyde；3-Methyl-5-phenyl-isoxazol-4-carbaldehyd；3-methyl-4-formyl-5-phenyl-1,2-oxazole；4-formyl-3-methyl-5-phenylisoxazole；3-methyl-5-phenyl-1,2-oxazole-4-carbaldehyde
• CAS: 89479-66-3
• 化学式: C₁₁H₉NO₂
• mdl: MFCD03086122
• 分子量: 187.198
• InChiKey: IZULDLZFUWWFHF-UHFFFAOYSA-N

物化性质

• 熔点：
  85 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 安全说明：
  S24/25

SDS

Name:	3-Methyl-5-phenyl-4-isoxazolecarbaldehyde 95+% Material Safety Data Sheet
Synonym:
CAS:	89479-66-3

Section 1 - Chemical Product MSDS Name:3-Methyl-5-phenyl-4-isoxazolecarbaldehyde 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
89479-66-3	3-Methyl-5-phenyl-4-isoxazolecarbaldeh	95+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 89479-66-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Needles
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 89 - 90 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H9NO2
Molecular Weight: 187.2

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 89479-66-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Methyl-5-phenyl-4-isoxazolecarbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 89479-66-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 89479-66-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 89479-66-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲基-5-苯基-4-异噁唑甲醛 在 盐酸 、 甲基溴化镁 作用下， 以 乙酸乙酯 为溶剂， 以96%的产率得到3-{[(2,5-二氯苯基)磺酰]氨基}苯酸酯
  参考文献：
  名称：

  Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases

  摘要：

  本发明提供了公式I的化合物：其中R1为H、CONH2、T(n)—R或T(n)—Ar2，n可以是零或一，而G、XYZ和Q如下所述。这些化合物是蛋白激酶的抑制剂，特别是JNK的抑制剂，JNK是一种参与细胞增殖、细胞死亡和对细胞外刺激反应的哺乳动物蛋白激酶。该发明还涉及生产这些抑制剂的方法。该发明还提供包含该发明中的抑制剂的药物组合物，并提供利用这些组合物在治疗和预防各种疾病中的方法。

  公开号：

  US20030149051A1
• 作为产物：
  描述：

  3-Methyl-5-phenyl-isoxazole-4-carbonitrile 在 盐酸 、 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 以57%的产率得到3-甲基-5-苯基-4-异噁唑甲醛
  参考文献：
  名称：

  Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases

  摘要：

  本发明提供了公式I的化合物：其中R1为H、CONH2、T(n)—R或T(n)—Ar2，n可以是零或一，而G、XYZ和Q如下所述。这些化合物是蛋白激酶的抑制剂，特别是JNK的抑制剂，JNK是一种参与细胞增殖、细胞死亡和对细胞外刺激反应的哺乳动物蛋白激酶。该发明还涉及生产这些抑制剂的方法。该发明还提供包含该发明中的抑制剂的药物组合物，并提供利用这些组合物在治疗和预防各种疾病中的方法。

  公开号：

  US20030149051A1

文献信息

• [EN] NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN<br/>[FR] NOUVEAUX COMPOSES DE PYRIDIN-2-ONE UTILISABLES EN TANT QU'INHIBITEURS DE THROMBINE
  申请人：ASTRAZENECA AB

  公开号：WO2005075424A1

  公开（公告）日：2005-08-18

  There is provided a compound of formula I, wherein the dashed line, R1, R2, R3a, R3b, A, D, E, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of thrombin is required or desired, and/or conditions where anticoagulant therapy is indicated).

  提供了一个式I的化合物，其中虚线、R1、R2、R3a、R3b、A、D、E、G和L的含义如描述中所示，这些化合物可用作竞争性蛋白酶抑制剂，如凝血酶，或者可用作其前药，特别适用于需要抑制凝血酶有益的情况的治疗（例如需要或希望抑制凝血酶的情况，如血栓栓塞等情况，以及需要抗凝治疗的情况）。
• Eine verbesserte Methode zur Synthese substituierter Isoxazol-4-carbaldehyde
  作者：Reinhard Heck、Roland Ofenloch、Roland Wolf

  DOI：10.1055/s-1990-26789

  日期：——

  An Improved Method for Synthesis of Substituted Isoxazole-4-carbaldehydes A series of isoxazole-4-carbaldehydes 3 have been readily prepared by simple oxidation of the corresponding isoxazolylalcohols 2 with sodium dichromate in dimethylsulfoxide.

  合成取代的异恶唑-4-甲醛的改进方法通过在二甲亚砜中用重铬酸钠简单氧化相应的异恶唑醇2，可以容易地制备一系列异恶唑-4-甲醛3。
• Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases
  申请人：Green Jeremy

  公开号：US20050026967A1

  公开（公告）日：2005-02-03

  The present invention provides compounds of formula I: where R 1 is H, CONH 2 , T( n )—R, or T( n )—Ar 2 , n may be zero or one, and G, XYZ, and Q are as described below. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

  本发明提供式I的化合物：其中R1为H、CONH2、T（n）—R或T（n）—Ar2，n可以为零或一，而G、XYZ和Q如下所述。这些化合物是蛋白激酶抑制剂，特别是JNK的抑制剂，JNK是哺乳动物蛋白激酶，涉及细胞增殖、细胞死亡和对细胞外刺激的反应。本发明还涉及制备这些抑制剂的方法。本发明还提供了包含本发明抑制剂的制药组合物和利用这些组合物在治疗和预防各种疾病的方法。
• Isoxazole derivatives
  申请人：——

  公开号：US20040048908A1

  公开（公告）日：2004-03-11

  A compound represented by the formula (I) 1 wherein one of R 1 and R 2 is a hydrogen atom or a substituent and the other is an optionally substituted cyclic group; W is a bond or a divalent aliphatic hydrocarbon group; Y is a group of the formula: —OR 3 (wherein R 3 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group) or an optionally esterified or amidated carboxyl group, or a salt thereof or a prodrug thereof has a superior insulin secretion promoting action and a hypoglycemic action and shows low toxicity. Therefore, the compound is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of diabetes and diabetic complications, and the like.

  化合物的化学式为（I）1，其中R1和R2中的一个是氢原子或取代基，另一个是可选取代的环状基团；W是键或二价脂肪基碳氢基团；Y是式子：—OR3的基团（其中R3是氢原子、可选取代的碳氢基团、可选取代的杂环基团或可选取代的酰基基团），或可选酯化或酰胺化的羧基团，或其盐或前药。该化合物具有优异的促胰岛素分泌作用和降血糖作用，并且毒性低。因此，该化合物可用作制药剂，特别是用作糖尿病和糖尿病并发症的预防或治疗剂等。
• Pyridin-2-one compounds useful as inhibitors of thrombin
  申请人：Bayrakdarian Malken

  公开号：US20070161643A1

  公开（公告）日：2007-07-12

  There is provided a compound of formula I wherein the dashed line, R 1 , R 2 , R 3a , R 3b , A, D, E, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of thrombin is required or desired, and/or conditions where anticoagulant therapy is indicated).

  提供了一种I式化合物，其中虚线，R1，R2，R3a，R3b，A，D，E，G和L的含义在说明书中给出，这些化合物可用作竞争性蛋白酶抑制剂，例如凝血酶，或可用作其前药，因此特别适用于治疗需要抑制凝血酶的情况（例如需要或期望抑制凝血酶的血栓栓塞等疾病，以及需要抗凝治疗的情况）。